Market Overview

Nanosphere Wins FDA Clearance to Market CYP2C19 Mutations Detection Test

Share:
Related NSPH
Benzinga's Top Initiations
Nanosphere Announces $10M Registered Public Offering Priced at $0.47 Per Share

Nanosphere, Inc. (Nasdaq: NSPH) announced today the US FDA granted 510(k) clearance permitting marketing of its CYP2C19 Nucleic Acid Test (CYP2C19 Test) on the automated sample-to-result Verigene^® System.

Posted-In: News FDA

 

Related Articles (NSPH)

View Comments and Join the Discussion!